Collectively, these findings highlight LAG-3 as a promising target in overcoming primary and acquired resistance to PD-1/PD-L1 blockade, and support the development of dual LAG-3/PD-1 targeting strategies as a next-generation immunotherapeutic approach in NSCLC (Table 1). Here, LAG3 is linked to non-small cell lung carcinoma.